195 related articles for article (PubMed ID: 37394372)
1. Humoral immune response following the inactivated quadrivalent influenza vaccination among HIV-infected and HIV-uninfected adults.
Liu Z; Pang C; Deng Y; Guo C; Li J; Li Y; Xin R; Li X; Xu C; Huang C; Lu H; Li J
Vaccine; 2023 Jul; 41(34):4978-4985. PubMed ID: 37394372
[TBL] [Abstract][Full Text] [Related]
2. Durability of antibody responses after receipt of the monovalent 2009 pandemic influenza A (H1N1) vaccine among HIV-infected and HIV-uninfected adults.
Crum-Cianflone NF; Iverson E; Defang G; Blair PJ; Eberly LE; Maguire J; Ganesan A; Faix D; Duplessis C; Lalani T; Whitman T; Brandt C; Macalino G; Millar EV; Burgess T
Vaccine; 2011 Apr; 29(17):3183-91. PubMed ID: 21371580
[TBL] [Abstract][Full Text] [Related]
3. Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial.
Forster AH; Witham K; Depelsenaire ACI; Veitch M; Wells JW; Wheatley A; Pryor M; Lickliter JD; Francis B; Rockman S; Bodle J; Treasure P; Hickling J; Fernando GJP
PLoS Med; 2020 Mar; 17(3):e1003024. PubMed ID: 32181756
[TBL] [Abstract][Full Text] [Related]
4. Factors associated with humoral immune response in older adults who received egg-free influenza vaccine.
Williams KV; Moehling Geffel K; Alcorn JF; Patricia Nowalk M; Levine MZ; Kim SS; Flannery B; Susick M; Zimmerman RK
Vaccine; 2023 Jan; 41(3):862-869. PubMed ID: 36543682
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults.
Crum-Cianflone NF; Eberly LE; Duplessis C; Maguire J; Ganesan A; Faix D; Defang G; Bai Y; Iverson E; Lalani T; Whitman T; Blair PJ; Brandt C; Macalino G; Burgess T
Clin Infect Dis; 2011 Jan; 52(1):138-46. PubMed ID: 21148532
[TBL] [Abstract][Full Text] [Related]
6. Standard-Dose Intradermal Influenza Vaccine Elicits Cellular Immune Responses Similar to Those of Intramuscular Vaccine in Men With and Those Without HIV Infection.
Amoah S; Mishina M; Praphasiri P; Cao W; Kim JH; Liepkalns JS; Guo Z; Carney PJ; Chang JC; Fernandez S; Garg S; Beacham L; Holtz TH; Curlin ME; Dawood F; Olsen SJ; Gangappa S; Stevens J; Sambhara S
J Infect Dis; 2019 Jul; 220(5):743-751. PubMed ID: 31045222
[TBL] [Abstract][Full Text] [Related]
7. Quadrivalent Influenza Vaccine-Induced Antibody Response and Influencing Determinants in Patients ≥ 55 Years of Age in the 2018/2019 Season.
Ganczak M; Dubiel P; Drozd-Dąbrowska M; Hallmann-Szelińska E; Szymański K; Brydak LB
Int J Environ Res Public Health; 2019 Nov; 16(22):. PubMed ID: 31739554
[TBL] [Abstract][Full Text] [Related]
8. Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy.
Pariani E; Boschini A; Amendola A; Poletti R; Anselmi G; Begnini M; Ranghiero A; Cecconi G; Zanetti AR
Vaccine; 2011 Nov; 29(49):9209-13. PubMed ID: 21974995
[TBL] [Abstract][Full Text] [Related]
9. Responses to pandemic ASO3-adjuvanted A/California/07/09 H1N1 influenza vaccine in human immunodeficiency virus-infected individuals.
Kelly D; Burt K; Missaghi B; Barrett L; Keynan Y; Fowke K; Grant M
BMC Immunol; 2012 Aug; 13():49. PubMed ID: 22937824
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine: a randomized, double-blind, controlled phase III clinical trial in children aged 6-35 months in China.
Hu Y; Shao M; Hu Y; Liang Q; Jia N; Chu K; Xu L; Li J; Li C; Zhu F
Hum Vaccin Immunother; 2020 Jul; 16(7):1691-1698. PubMed ID: 32347785
[TBL] [Abstract][Full Text] [Related]
11. A Prospective Immunogenicity Study of a Quadrivalent Inactivated Influenza Vaccine Among Persons With HIV With Different Levels of CD4 Cell Count.
Satanon S; Kiertiburanakul S; Boonnak K; Bruminhent J
J Acquir Immune Defic Syndr; 2023 Jul; 93(3):251-259. PubMed ID: 36881814
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: a phase II, open-label, uncontrolled trial in Japan.
Tsurudome Y; Kimachi K; Okada Y; Matsuura K; Ooyama Y; Ibaragi K; Kino Y; Ueda K
Microbiol Immunol; 2015 Oct; 59(10):597-604. PubMed ID: 26272602
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety of Quadrivalent Influenza HA vaccine in Indonesian children: An open-labeled, bridging, clinical study.
Dhamayanti M; Tarigan R; Fadlyana E; Prasetyo D; Amalia N; Rusmil VK; Sari RM; Bachtiar NS; Rusmil K; Kartasasmita CB
Vaccine; 2020 Jan; 38(5):993-1000. PubMed ID: 31862195
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the Immunogenicity of Cell Culture-Based and Recombinant Quadrivalent Influenza Vaccines to Conventional Egg-Based Quadrivalent Influenza Vaccines Among Healthcare Personnel Aged 18-64 Years: A Randomized Open-Label Trial.
Dawood FS; Naleway AL; Flannery B; Levine MZ; Murthy K; Sambhara S; Gangappa S; Edwards L; Ball S; Grant L; Belongia E; Bounds K; Cao W; Gross FL; Groom H; Fry AM; Rentz Hunt D; Jeddy Z; Mishina M; Kim SS; Wesley MG; Spencer S; Thompson MG; Gaglani M
Clin Infect Dis; 2021 Dec; 73(11):1973-1981. PubMed ID: 34245243
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: a phase III, randomized trial.
Tinoco JC; Pavia-Ruz N; Cruz-Valdez A; Aranza Doniz C; Chandrasekaran V; Dewé W; Liu A; Innis BL; Jain VK
Vaccine; 2014 Mar; 32(13):1480-7. PubMed ID: 24486352
[TBL] [Abstract][Full Text] [Related]
16. Induction of Cross-Reactive Hemagglutination Inhibiting Antibody and Polyfunctional CD4+ T-Cell Responses by a Recombinant Matrix-M-Adjuvanted Hemagglutinin Nanoparticle Influenza Vaccine.
Shinde V; Cai R; Plested J; Cho I; Fiske J; Pham X; Zhu M; Cloney-Clark S; Wang N; Zhou H; Zhou B; Patel N; Massare MJ; Fix A; Spindler M; Thomas DN; Smith G; Fries L; Glenn GM
Clin Infect Dis; 2021 Dec; 73(11):e4278-e4287. PubMed ID: 33146720
[TBL] [Abstract][Full Text] [Related]
17. Enhancing effects of adjuvanted 2009 pandemic H1N1 influenza A vaccine on memory B-cell responses in HIV-infected individuals.
Ho J; Moir S; Wang W; Posada JG; Gu W; Rehman MT; Dewar R; Kovacs C; Sneller MC; Chun TW; Follmann DA; Fauci AS
AIDS; 2011 Jan; 25(3):295-302. PubMed ID: 21157297
[TBL] [Abstract][Full Text] [Related]
18. Key differences in B cell activation patterns and immune correlates among treated HIV-infected patients versus healthy controls following influenza vaccination.
Luo Z; Ma L; Zhang L; Martin L; Wan Z; Warth S; Kilby A; Gao Y; Bhargava P; Li Z; Wu H; Meissner EG; Li Z; Kilby JM; Liao G; Jiang W
Vaccine; 2016 Apr; 34(16):1945-55. PubMed ID: 26721328
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and sustainability of the immune response in Brazilian HIV-1-infected individuals vaccinated with inactivated triple influenza vaccine.
Souza TM; Santini-Oliveira M; Martorelli A; Luz PM; Vasconcellos MT; Giacoia-Gripp CB; Morgado M; Nunes EP; Lemos AS; Ferreira AC; Moreira RI; Veloso VG; Siqueira M; Grinsztejn B; Camacho LA
J Med Virol; 2016 Mar; 88(3):426-36. PubMed ID: 26267817
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of Quadrivalent Influenza HA vaccine compared with Trivalent Influenza HA vaccine and evaluation of Quadrivalent Influenza HA vaccine batch-to-batch consistency in Indonesian children and adults.
Fadlyana E; Dhamayanti M; Tarigan R; Prodjosoewojo S; Rahmadi AR; Sari RM; Rusmil K; Kartasasmita CB
PLoS One; 2023; 18(8):e0281566. PubMed ID: 37616221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
